Stockscreener 앱 받기
2.05
4.65%
-0.10
시간 외 거래:
2.00
-0.05
-2.44%
전일 마감가:
$2.15
열려 있는:
$2.11
하루 거래량:
152.12K
Relative Volume:
1.02
시가총액:
$113.90M
수익:
-
순이익/손실:
$-21.38M
주가수익비율:
-5.2564
EPS:
-0.39
순현금흐름:
$-25.19M
1주 성능:
-0.97%
1개월 성능:
+40.41%
6개월 성능:
+122.25%
1년 성능:
+73.73%
1일 변동 폭
$1.88
$2.14
1주일 범위
$1.88
$2.46
52주 변동 폭
$0.51
$2.86
코넥트 바이오파마 Stock (CNTB) Company Profile
명칭
Connect Biopharma Holdings Ltd Adr
전화
858-727-1040
주소
3580 CARMEL MOUNTAIN ROAD, SUITE 200, SAN DIEGO
CNTB을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CNTB
Connect Biopharma Holdings Ltd Adr
|
2.05 | 119.46M | 0 | -21.38M | -25.19M | -0.39 |
|
VRTX
Vertex Pharmaceuticals Inc
|
392.79 | 100.07B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
580.41 | 59.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
448.91 | 58.03B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
653.83 | 39.93B | 3.06B | 1.28B | -614.78M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
321.36 | 36.82B | 3.81B | -644.79M | -669.77M | -6.24 |
코넥트 바이오파마 Stock (CNTB) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-06-12 | 개시 | H.C. Wainwright | Buy |
| 2024-03-04 | 개시 | H.C. Wainwright | Buy |
| 2021-04-13 | 개시 | Jefferies | Buy |
| 2021-04-13 | 개시 | Piper Sandler | Overweight |
| 2021-04-13 | 개시 | SVB Leerink | Outperform |
코넥트 바이오파마 주식(CNTB)의 최신 뉴스
Connect Biopharma Posts Q2 Revenue Drop - AOL.com
Connect Biopharma Reports Q2 Revenue Drop of 99.2% to $48,000, R&D Spending Increases 65.6% to $8.8mln - AInvest
Connect Biopharma Posts Q2 Revenue Drop - The Motley Fool
Connect Biopharma Holdings Ltd SEC 10-Q Report - TradingView
Connect Biopharma Reports Second Quarter 2025 Financial Results and Provides Business Update - GlobeNewswire
Connect Biopharma Holdings Limited shares rise 5.63% after-hours following Jazz Pharmaceuticals' FDA approval of Modeyso. - AInvest
Connect Biopharma Shares Rise on Plan to End ADR Program and Directly List on Nasdaq - MSN
What Makes Connect Biopharma Holdings Limited Sponsored ADR (CNTB) a Strong Momentum Stock: Buy Now? - Yahoo Finance
Research Analysts Set Expectations for CNTB Q2 Earnings - MarketBeat
Connect Biopharma (NASDAQ:CNTB) Upgraded at Northland Capmk - Defense World
Q2 Earnings Estimate for CNTB Issued By Northland Capmk - Defense World
Connect Biopharma stock rating reiterated as Outperform by Northland - Investing.com Australia
Connect Biopharma appoints Jim Schoeneck to board of directors By Investing.com - Investing.com Nigeria
Connect Biopharma appoints Jim Schoeneck to board of directors - Investing.com Australia
Connect Biopharma appoints James A. Schoeneck to board of directors By Investing.com - Investing.com Nigeria
Northland starts Connect Biopharma at Outperform on chance to define new class - TipRanks
Connect Biopharma stock rises after announcing plan to terminate ADR program - Investing.com
Connect Biopharma to terminate ADR program, list ordinary shares By Investing.com - Investing.com India
Connect Biopharma to terminate ADR program, list ordinary shares - Investing.com
Connect Biopharma to Terminate ADR Program and List Ordinary Shares on Nasdaq - Nasdaq
Connect Biopharma Announces Plans to Terminate its American - GlobeNewswire
Connect Biopharma Streamlines Trading: ADRs Convert to Direct Nasdaq Shares in Major US Market Push - Stock Titan
Connect Biopharma Terminates ADR Program, to List Ordinary Shares on Nasdaq - AInvest
Connect Biopharma regains Nasdaq compliance with minimum bid price rule - Investing.com India
Connect Biopharma regains Nasdaq compliance with minimum bid price rule By Investing.com - Investing.com South Africa
Connect Biopharma regains Nasdaq compliance with $1 minimum bid price - Investing.com
Connect Biopharma Holdings shares rise 7.89% in after-hours after partner's new drug application for atopic dermatitis is accepted by NMPA. - AInvest
Connect Biopharma’s partner submits new drug application in China - Investing.com
Connect Biopharma’s partner submits new drug application in China By Investing.com - Investing.com South Africa
Connect Biopharma (NASDAQ:CNTB) Trading Down 2.5% – Here’s What Happened - Defense World
Connect Biopharma reports positive data for asthma treatment By Investing.com - Investing.com South Africa
Connect Biopharma reports positive data for asthma treatment - Investing.com
Connect Biopharma begins Phase 2 asthma study - Investing.com
Connect Biopharma stock hits 52-week low at $0.55 amid market challenges By Investing.com - Investing.com South Africa
Connect Biopharma stock hits 52-week low at $0.55 amid market challenges - Investing.com
FDA greenlights Connect Biopharma’s asthma and COPD trials - Investing.com
Connect Biopharma stock holds $8 target, Buy rating at H.C. Wainwright - Investing.com
Connect Biopharma shares rise 1.62% after-hours following positive FDA feedback on Phase 2 trials for asthma and COPD treatments. - AInvest
Connect Biopharma faces Nasdaq delisting over share price By Investing.com - Investing.com India
Connect Biopharma faces Nasdaq delisting over share price - Investing.com
Connect Biopharma stock hits 52-week low at $0.76 - Investing.com
Connect Biopharma stock hits 52-week low at $0.91 amid market challenges - Investing.com India
Form N-CSR FIDELITY CONCORD STREET For: Nov 30 - StreetInsider.com
Top 3 Aerospace and Defense Stocks Flying Under the Radar - The Globe and Mail
Is Connect Biopharma Holdings (CNTB) Stock Outpacing Its Medical Peers This Year? - Nasdaq
Stocks Set to Open Lower as Investors Await Fed Meeting, Banking Sector Remains in Focus - Barchart.com
코넥트 바이오파마 (CNTB) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.41%
0.88%
자본화:
|
볼륨(24시간):